RxDoctor Payments Data

Zachary Robinett, MD

Otolaryngology · North Logan, UTNPI 1316351380

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.2%. 2025 is the largest year on record at $1,001, 2.3 times the $435 reported in 2019.

$4,393in general payments, 2019–2025

Across 121 payments — averaging $36.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$668
  • Medical Device Business Services, Inc.$614
  • Medtronic$594
  • Johnson & Johnson$422
  • Smith+Nephew$342
  • Sanofi$248
  • plus $2K from 25 others

What the payments were for

  • Travel & lodging$1,61637%
  • Food & beverage$2,59759%
  • Education$1804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,393 in reported general payments places this provider in the 80th percentile of 104 otolaryngology providers in Utah.

See all otolaryngology providers in Utah

Medicare billing

Part B allowed, 2024
$112,014
Medicare patients
279
Services billed
1,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium34$2,634
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$1,600
Ofloxacin27$761
Omeprazole48$644
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen48$510
Cephalexin50$501
Clarithromycin15$489
Mupirocin54$472
Liothyronine Sodium16$434
Azelastine Hcl16$367
Levothyroxine Sodium33$268
Methimazole11$238
Ondansetron OdtOndansetron32$197
CefuroximeCefuroxime Axetil12$158
Zolpidem Tartrate16$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$81$2,63434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 104 otolaryngology providers in Utah.

Other otolaryngology in North Logan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →